Better Clinical Outcomes Seen With Fetroja as Empiric, Not Salvage Therapy

A higher clinical cure rate was found among patients with serious gram-negative bacterial infections who received ...

APRIL 16, 2025

Cefiderocol May Be Game Changer for Acinetobacter

Cefiderocol may be a game changer for treating resistant Acinetobacter in patients with limited or no alternative ...

FEBRUARY 21, 2025

Cefiderocol Proves Efficacious, Well Tolerated in Real-World Data

PROVE trial results show Fetroja was efficacious and well tolerated in the treatment of serious gram-negative ...

OCTOBER 18, 2024

New Guidance for AMR Gram-Negative Infections

The Infectious Diseases Society of America recently updated guidance for the treatment of antimicrobial-resistant ...

AUGUST 23, 2024

Right Drug for the HABP and VABP Patient

Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are among the most common and ...

AUGUST 23, 2023

Take Advantage of Newer Antibiotic Options

Antibiotic-resistant infections and deaths increased by 15% during the pandemic, according to the Infectious ...

OCTOBER 13, 2022

Novel Entry Helps Fetroja Defeat Bacteria in Difficult to Treat Infections

Cefiderocol binds to iron, tricking the bacteria into engulfing the drug along with this vital nutrient, through ...

FEBRUARY 8, 2021

FDA Grants HABP/VABP Indication for Fetroja

The FDA approved a new indication for cefiderocol to treat adults with hospital-acquired bacterial pneumonia and ...

SEPTEMBER 29, 2020